Latest Conference Articles

A modified dosing schedule of frontline nivolumab (Opdivo) and ipilimumab (Yervoy) compared with the standard dose showed no differences in responses or safety in patients with advanced renal cell carcinoma, according to results of the CheckMate-920 trial.

Low-Dose Lenvatinib Shows Similar Safety to Standard Dose in RCC, But Noninferiority Cannot Be Claimed

November 7th 2020, 9:42pm

A 14-mg dose of lenvatinib showed similar safety to the standard 18-mg dose of the agent, when used in combination with everolimus in the second-line treatment of patients with advanced renal cell carcinoma, but noninferiority could not be confirmed.

Future of VHL Disease–Associated RCC Bright, With Immunotherapy and HIF-2α, CDK4/6 Inhibitors Part of Ongoing Research

November 7th 2020, 9:15pm

Recent research for effective therapies designed to target von Hippel-Lindau disease–associated renal cell carcinoma is pointing to a future with the paradigm that comprises immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors.

Choosing Among First-Line IO/TKI Combos in RCC: The Affordable Option Is the Winner

November 7th 2020, 8:38pm

Combination regimens comprised of immunotherapy and TKI inhibitors have yielded significant benefits in terms of overall survival and progression-free survival with acceptable safety in patients with renal cell carcinoma; however, the cost of these regimens may negate the impact of these advances.

Management of Small Cell Lung Cancer Moves Forward With Immunotherapy

November 7th 2020, 8:30pm

Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.

Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing

November 7th 2020, 6:26pm

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Dr. Rohs on the Importance of Genetic Testing in NSCLC

November 7th 2020, 5:00pm

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Dr. Rizk on the Evolution of Surgery in Lung Cancer

November 7th 2020, 5:00pm

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Dr. McGregor the Potential Utility of Cabozantinib/Nivolumab in Advanced RCC

November 7th 2020, 11:30am

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Dr. Choueiri on the Rationale for the COSMIC-313 Trial in Advanced RCC

November 7th 2020, 11:30am

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Lenvatinib/Pembrolizumab Shows Promise After PD-1/PD-L1 Inhibition in Metastatic Clear Cell RCC

November 6th 2020, 11:17pm

The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.

Need for Germline Testing Becomes Increasingly Pronounced in Oncology

November 6th 2020, 11:14pm

Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.

Dr. Rini on Choosing Between IO/IO or IO/TKI Combinations in mRCC

November 6th 2020, 10:43pm

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Frontline Lenvatinib/Everolimus Combo Is Active in Non-Clear Cell RCC

November 6th 2020, 8:16pm

The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.

Cabozantinib Is Center of Emerging Treatment Approaches in Advanced RCC

November 6th 2020, 6:49pm

Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.

NCI Director Talks Response to COVID-19 Crisis, Focuses on Overcoming Disruptions in Cancer Care

November 6th 2020, 5:14pm

Norman E. “Ned” Sharpless, MD, discusses the efforts that The National Cancer Institute has made to combat the coronavirus disease 2019 pandemic.

Hudis Emphasizes Need for Cancer Research Funding During CFS® Keynote

November 6th 2020, 3:44pm

Clifford A. Hudis, MD, CEO highlights cancer mortality and how it has steadily declined in the United States since 1975.

Unlocking the Potential of Targeted Treatment Options for HCC

November 6th 2020, 3:38pm

Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.

Immunotherapy in Gynecologic Cancers Shows Progress but Has a Long Way to Go

November 5th 2020, 7:39pm

Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.

Dr. Jhaveri on Outlining First-Line Treatment in HER2+ Breast Cancer

November 5th 2020, 7:00pm